The comments
on the previous web-pages strongly suggest that dietary insufficiency may contribution
to the
development of the symptomatology associated with Dementia and Alzheimer's disease. To date
there have been no definitive trials that have shown that nutrient
supplementation can halt or reverse the development of Alzheimer's disease,
however, none of the previous trials have addressed the causes as outlined
previously. It is hoped that this page can provide a number of potential areas
of nutritional supplementation that may be beneficial in the prevention of AD,
and possibly halt or reverse early signs of dementia, and prevent dementia.
The current Rate of Dementia at an all-time high:
The risk of someone developing dementia in the US is now estimated at one in
two.
Currently nearly 8 million Americans currently have some form of dementia and
there are around 500,000 new cases diagnosed per year. It is postulated that
mutations in ApoE are risk factors for dementia, however the rate of the
relevant ApoE mutation is only one in 257, so it is highly unlikely that has any
major contribution to the 50% of the population destined to get dementia. Hence
attention needs to concentrate on modifiable factors.
Identified risk factors include
less education,
hearing impairment, smoking, depression, physical inactivity, traumatic brain
injury, high blood pressure, social isolation, air pollution, diabetes, obesity,
high cholesterol and excessive alcohol consumption. Lack of or poor sleep is
also a risk factor. Of these high blood pressure, diabetes, and obesity can be
due to
functional B2 deficiency, whilst high cholesterol and poor sleep
are due to
functional B12 deficiency. Functional B2 deficiency (due to Iodine, Selenium
and/or Molybdenum deficiency) causes functional B12 deficiency, leading to
elevated homocysteine, nerve demyelination, reduced production of creatine, lower
production of CoQ10, lower production of acetylcholine, elevated cholesterol, lower activity of aconitase, and succinic anhydride, all typical of AD.
Lowering Homocysteine: Clearly lowering
homocysteine is desirable. This can be achieved through dietary intake of
sufficient folate, vitamin B6, iron, vitamin B2 (plus Iodine, Selenium and
Molybdenum) and vitamin B12. In individuals
with suspected hypothyroidism this should be treated/corrected and dietary
iodine, selenium and molybdenum included or supplemented. Treatment of vitamin B12 this is a little
bit more difficult as once a person becomes deficient, it is very hard to
achieve sufficiency through diet. Further, many people do not gain benefit even
from injection of the provitamins cyanocobalamin or hydroxocobalamin and so
mixed adenosyl/methyl cobalamin supplementation would be desirable. There have
been many oral supplementation trials examining the effect of high dose
cyanocobalamin and folate +/- other B group vitamins on lowering homocysteine
and attempting to increase the Mini-Mental State Examination (MMSE) scores
(reviewed in (1)). Whilst some of the trials were successful in lowering
homocysteine no trial using oral supplementation achieved an increase in MMSE.
Despite this the trials have been repeated over and over again, and in an almost
"Ground hog" like fashion have repeatedly administered oral high dose
cyanocobalamin and folate +/- other B groups, and expected or hoped for a
different result. Further the importance of functional vitamin B2 in the cycling
of both folate and vitamin B12 has been almost completely over-looked in all
reviews. Thus, the lack of success following orally administered mixtures of
folate, vitamin B12 (the inactive cyanocobalimin analogue), plus vitamin B6, is
totally expected, firstly because the delivery of vitamin
B12 to the brain is exceedingly difficult and secondly the amount of vitamin B12 taken up
from the gut is very low, and third, functional vitamin B2 sufficiency is
essential for maintenance of vitamin B12 activity. In line with what is known about the blood-brain
barrier, even the smallest of water soluble molecules is actively excluded from
entering the brain. Further, even with the injection of radiolabeled vitamin B12
derivatives less than 0.01% of the dose reaches the brain. Little wonder then that
the very limited uptake that is achievable from oral delivery of vitamin B12
has been found to be totally ineffectual in "loading" up the brain.
Vitamin B12:
Vitamin B12 plays a critical role in myelination, both in the provision of the
methyl group for methylation of myelin basic protein and also in the correct
processing of methyl malonic acid. Vitamin B12 lack has been associated with
incorporation of faulty lipids into the myelin sheath and in the production of
faulty myelin basic protein, and destruction of the myelin sheath is a feature
of vitamin B12 deficiency. Formation of melatonin requires methylation,
and maintenance of the myelin sheath requires melatonin and vitamin D. Levels of
Melatonin decrease with age. Demyelination is a feature of Alzheimer's disease,
and loss of myelinated axons has been found in AD(2).
Overt vitamin B12 deficiency is
correlated negatively with cognitive functioning, and is associated with memory
impairment, slowness of thought, attention deficits and dementia (3,4,5). It is
also associated with decreased nerve conduction velocity (6).Whilst overt B12
deficiency is easily defined levels of B12 even as high as 350 pmol/L have been
associated with brain shrinkage, which has also been shown to be associated with
cognitive decline (7,8). It would therefore appear logical to maintain vitamin
B12 levels that are considerably higher than this. The close relationship
between folate and vitamin B2 with maintaining methyl B12 levels, would intimate
that it is also essential to maintain adequate levels of these two vitamins as
well. In this regard, it has been shown that supplementation with folic acid,
vitamin B6 and vitamin B12 was able to slow brain shrinkage in elderly subjects
with increased dementia risk (8,9,10,11,12). Unfortunately they did not go
further and also supplement with vitamin B2. This is despite the fact that functional vitamin B2 has been known to be
essential for maintenance of functional vitamin B12, particularly methyl B12,
for over 50 years yet review after review and study after study fails to
acknowledge or account for possible lack of functional B2 activity. Despite this
study after study, funded by grant after grant has been performed and has not
included any of B2/I/Se/Mo in the protocol. To date we could find only one supplementation study has been performed with B2/B12/folate,
in combination with
Iodine, Selenium and Molybdenum, all three of which are required for formation
of the two active forms of vitamin B2, viz FMN and FAD (13).
There was however, no change in cognitive functions found following
supplementation, possibly due to the use of selenomethionine as the source of
selenium. Selenomethionine has repeatedly failed to change markers of vitamin B2
activation in our hands. Vitamin B12 supplementation is also warranted due to the role of Methyl B12 in
the formation of choline and the findings of greatly reduced levels of B12 in
the brains of elderly persons (14). Vitamin B12 intake should
equal or exceed 6 ug/day in persons who do not have other underlying
complications, such as sub-optimally treated hypothyroidism, use of PPIs, GORD
medication, pernicious anaemia, use of MetforminTM medication, the presence of
atrophic gastritis, or other B12 modifying conditions. It should also be noted
that it is highly unlikely that orally administered vitamin B12 would ever
deliver sufficient B12 to overcome deficiency in the brain. First, the amount of
B12 taken up from the gut is maximally 6-10 ug, and of this less than 0.1% ever
reaches the brain. In these cases higher
supplementation should be attempted either by injection or by other high
supplementation methods, such as transdermal application. It should be
noted, that successful cycling of vitamin B12, particularly methyl B12 requires
functional vitamin B2, which in turn requires adequate intake of Iodine (150-300
ug/day), selenium (55-200 ug/day) and molybdenum (100-200 ug/day). I/Se/Mo are
not normally incorporated in most multi-vitamin formulations, although this is
changing. In this regard, the two main enzymes that support vitamin B12 cycling
are both B2 dependent, viz: MTHFR and MTRR. The activity of both enzymes has
been shown to be critically dependent upon riboflavin status, and a dramatic
drop in activity is seen in the two common variants of MTHFR (677C>T) and MTRR
(66A>G) in suboptimal riboflavin concentrations (15). It is surprising, then,
that supplementation studies have not addressed these probable deficiencies,
particularly since the frequency of these mutations is very high. More recently, the
incidence of Paradoxical B12 deficiency has risen dramatically. In this
condition levels of serum vitamin B12 may be normal or elevated, however,
markers of functional vitamin B12 deficiency are also elevated - a situation of
Paradoxical B12 deficiency. Rate of
brain atrophy has been slowed by ultra-high dose administration of a mixture of
L-methylfolate, methylcoblamin, and N-acetyl cysteine (16) administered by injection. Successful
reversal of fronto-temporal dementia has been reported in an elderly gentleman
who was given repeated injections of high dose vitamin B12 (17). Whilst broad
neurological disorders, including poor Hasegawa dementia scale ratings were
greatly improved by supplementation with high dose injected methylcobalamin
(18). Similarly improvement in cognitive function was also achieved by
intravenous methylcobalamin (19). MethylB12
due to its role in recycling homocysteine, methionine and eventually S-Adenosylmethionine,
also has a critical role in the production of creatine, and creatine-phosphate,
and also in the production of ubiquinone. Lack of production of creatine, and/or
ubiquinone have both been correlated with lower cognitive function and
intellectual disability. Serum coenzyme Q10 have been found to be inversely
associated with the risk of disabling dementia. For some reason, methyl-B12's
critical role in the production of these very important energy related molecules
has been missed by all but a few who work in the field. Melatonin
levels are also dependent upon methyl B12, due to the role of methylation in the
conversion of serotonin to melatonin. Melatonin has been shown to have a very
important role in maturation of myelin producing oligodendrocytes (20),
and in promoting myelination during development and after neuronal damage (21,22,23,24,25).
This activity would be compromised in vitamin B12 deficiency and would
contribute to the observed reduced myelin sheath thickness characteristic of the
aged brain. (see above). Maintenance of
functional vitamin B12 requires not only daily ingestion of vitamin B12, but
also vitamin B2, Iodide (150 ug/day), Selenium (as Selenite, 55 ug/day), and
Molybdenum (100 ug/day).
Selenium:
Recently, a very encouraging study was carried out using sodium selenate at a
quite high concentration (0.32 mg and 3.0 mg qdx3) (26).
In the 24 weeks study, brain selenium concentration was raised and MMSE did not
fall when compared to controls. Other biochemical markers were not reported.
Sodium selenate supplementation of mice reversed hippocampal-dependent learning
and memory impairments (45)
It must be noted that studies with selenomethionine have not been shown to
affect MMSE.
Iron: Supplementation with heme iron or
addition of iron containing foods may be of benefit. Measurement of iron
deficiency as per levels of serum ferritin is highly controversial, but it is
generally agreed that iron deficiency anaemia occurs at around 20 ug/L ferritin,
mild iron deficiency initiating symptoms such as restless leg syndrome occurring
at round 50 ug/L with some evidence of iron deficiency occurring between 50-100
ug/L. Evidence of reduced mitochondrial energy output is definitely apparent at
levels below 70 ug/L ferritin. Data looking at ferritin levels, in individuals
where one would assume maximum benefit from iron would be desirable, have shown
that the highest performing athletes had levels of between 80-185 ug/L (mean 134
ug/L)(2). Iron intake should equal or exceed 9 mg/day for men and
post-menopausal women. Studies looking at chronic heart failure suggest that
levels below 100 ug/L ferritin are of potential risk. It is apparent that as
iron levels decrease, iron is lost from muscles, brain and heart, and lack of
iron in muscles can account for the frailty, which is characteristic of
dementia. The enzyme, aconitase starts to uncouple when ferritin levels are
lower than 50 ug/L, and the activity of the Electron Transport Chain decreases
as levels of iron decrease. Vitamin B12, through its action on the sulphation
pathway is essential for the formation of iron-sulphur (Fe-S) clusters, and
these are essential elements of aconitase (in Krebs cycle), and there are
multiple Fe-S clusters in Complex I, II and Complex III of the Electron
Transport Chain. Fe-S clusters are also essential for processing Molybdenum, and
the formation of the Molybdenum cofactors in enzymes such as sulfite oxidase,
xanthine dehydrogenase, aldehyde oxidase, and miochodrial amidoxime reductase.
Intracellular processing of iron requires FAD (from B2), and GSH.Without these
the soluble Fe2+ form of iron is readily oxidized to Fe3+, which is insoluble
and can precipitate within the cell, adn cause ferroptosis. Ferroptosis is a
feature of diseases such as AD, PD
Aconitase:
Aconitase is arguably one of the most important enzymes in the citric acid
cycle, and reduced activity of the enzyme, due to lack of formation of iron-sulphur
complexes will lead to a greatly decreased energy output by the mitochondria.
Enzymatic activity has been shown to be reduced in conditions of sub-optimal
iron concentrations and sub-optimal sulphur concentrations. Increasing levels of
iron/ferritin and conditions that increase the processing of sulphur from
dietary methionine, should favour increased aconitase activity. The inflection
point for loss of aconitase activity is around 70 ug/L ferritin, which is
considerably higher than many pathology laboratories would "flag" as deficiency.
Thus, potentially many individuals with sub-optimal iron levels are not being
treated for non-anaemic iron deficiency. Thus,
maintenance of sufficient iron in the diet, plus intake of sulphur in the form
of methionine, and ensuring sufficient vitamin B2 and vitamin B6 would all help
to provide sufficient iron and sulphur to maintain the activity of aconitase. In
addition it has been shown that elevated production of S-Adenosylmethionine
(SAM) is required in order to move sulphur from the methylation cycle to the
sulphation cycle for incorporation into Fe-S proteins. This further predicates
the maintenance of high levels of active vitamin B12, sufficient folate and
active vitamin B2.
Hydrogen sulfide:
Given that generation of H2S occurs as a result of processing of homocysteine by
the enzyme cystathionine beta synthase, conditions that increase the processing
of homocysteine by CBS will also increase the production of CBS, viz: increased
iron, B6 and B2, and increased dietary methionine, elevated vitamin B12, and
sufficient folate.
Acetylcholine: Studies examining plasma
phosphatidylcholine docosahexaenic acid (DHA) showed that those who had a higher
mean intake of DHA had a significant (47%) reduction in the risk of developing
all-cause dementia (20). This is in contrast to studies in
which lecithin supplementation did not affect the risk of development of
dementia (21). Dietary supplementation with egg yolk phosphatidylcholine has shown memory improvement in models of AD (22). Once again supplementing with methyl B12, folate and vitamin B2 should
increase methylation and formation of choline and acetylcholine, which should
help to reduce the rate of degeneration of cholinergic neurons, which is a
feature of AD (27,28,29).
Increased blood supply to the brain: The
mantra for preventing AD has for a long time been "diet and exercise", however,
the benefits of this are generally not explained. Evidence suggests that there
is restricted blood supply to the brains in AD, and the thought is that
increasing the exercise regime will increase the blood supply to the brain.
There is potentially a nutritional way to increase blood supply to the brain and
that is by providing iron, FMN/FAD and BH4 for increasing the activity of the
enzyme, NOS. Increased generation of the vasodilator nitric oxide by eNOS, has
been shown to increase cognitive function (30). Aberrant NOS activity is a
feature of AD (31). Reduced NOS activity has
also been shown to increase the formation of amyloid precursor protein (32).
Boyle and co-workers (33)
found a correlation between lack of physical activity, increased weight and
brain atrophy in AD. Somewhat at odds with this finding was the lack of
correlation between elevated systolic blood pressure and dementia in those above
80 (34).
Vitamin D:
As discussed previously Hypovitaminosis D, is associated with brain
changes and an increased risk of dementia, further it has even been found
that vitamin D supplementation can slow, prevent or improve neurocognitive
decline (42). It would therefore appear obvious that persons should make sure
that they obtain plenty of vitamin D, either through sun-exposure or through
diet, and that they should maintain sufficient iron/vitamin B2/vitamin B12 in
order to activate vitamin D to its active form 1,25-diOHD (Calcitriol). Avoid
using extremely high SPF cosmetics, which have now become the "norm". Suggested
levels of calcidiol are above 75 ng/ml. In addition, due to potential vitamin D
lowering effects of statins, it would be prudent to avoid their use.
Lack of vitamin D has also been associated with a loss in hippocampal volume (an
area of the brain that regulates motivation, emotion, learning and memory), and
hence low vitamin D would be associated with difficulty learning. Low vitamin D
has been associated with cognitive decline in adults (Wentz etal, 2014). Low
vitamin D in utero has been associated with autism spectrum disorder and
schizophrenia (Eyles etal, 2013; Ali etal, 2020, 2018), whilst in adults it has been associated with
depression and Alzheimer's disease Littlejohns etal, 2014; 2016; Dickens etal,
2011).
The importance of sun-exposure for the production of
vitamin D has been known 1822 (nearly 200 years), and particularly exposure to
UVB radiation (290-315 nm) (Holick 2006). However with the advent of
sun-protection factors in the early 1870s, and the addition of high SPF value cosmetics and the
increase in hours worked indoors, plus various sun-avoidance practices has seen a rise in the incidence of vitamin D
deficiency, and an increase in the incidence of rickets with the result that
vitamin D deficiency in children has once again reached epidemic proportions (Holick
2006). One of the potential sources of vitamin D is dairy, and so, the reduction in the consumption of dairy products,
particularly those from free range cows and the
switch to alternative products such as soy, and almond drinks, and adoption of a
vegan diet can further reduce vitamin D levels.. Vitamin D deficiency is very
common in some countries, and over 42% of Singapore residents (92),
45.5% of Saudi residents, and in 2018 over 82.5% of females in South Korea (an
increase from 76% in 2008)(93)
were found to be vitamin D deficient. Patients with vitamin D serum levels of
<25 mg/ml had an increased risk of developing Alzheimer's Disease in comparison
with those >25 mg/ml. Severe deficiency had the strongest association. Vitamin D
has been shown to prevent cognitive dysfunction via neuroprotection, neurotrophy,
neurotransmission, and neuroplasty. Rates of vitamin D sufficiency have fallen
by 40% over the past 10 years, which is inversely proportional to the doubling
of the incidence of Alzheim's disease from 60/100,000 to 120/100,000 in the
UK (
Mode of activation of Vitamin D in the brain, following stimulation of the eye
by 482 nm light.
"Nexus Theory™" and Dementia: Recently, it has become apparent that
activation of vitamin D to form the active form, calcitriol, is not quite as
simple as one would imagine. Thus, whilst most enzymatic reactions only involve
the activity of one enzyme, the conversion of 25-hydroxy-vitamin D to the active
form 1,25-dihydroxyvitamin D (calcitriol) involves a multi-enzyme complex, which
consists of CYP27B1 (25-hydroxyvitamin D3 1-alpha-hydroxylase), Adrenodoxin
(an Iron-sulphur protein) and Adrenodoxin reductase (an NADPH/.FAD enzyme).
Generally this activity is performed in the kidney, but it has been found that a
similar assembly system exists in the brain. Thus, there is a joining or Nexus
of enzymes requiring vitamin D, Iron, vitamin B2 (as FAD), and an iron-sulphur
complex, wherein the sulphur for such complex is critically dependent upon the
activity of the methylation cycle as ipso facto, methyl vitamin B12. A corollary
to the "Nexus Theory™ is that any attempt to reverse the damage that has
occurred in the early stages of the development of dementia, must address all of
the above deficiencies, because if it does not such attempts will not succeed.
Further, when one considers the multi-component nature of the "Nexus Theory™",
one can see how so many known deficiencies contribute to the condition. Thus, Vitamin D (as 1,25 dihydroxyvitamin D - the active
form) has a critical role in remyelination in damaged nerves and in the initial
myelination of nerves, and in the processes involved in "neuronal plasticity".
Oligodendrocytes (the cells that make the myelin sheath) are stimulated to
produce myelin by binding active vitamin D. This then works in concert with
melatonin (a methylation dependent hormone) to stimulate mitochondrial energy
production in neurones, and to activate the oligodendrocytes. The "Nexus Theory™
of Dementia thus encompasses the known deficiencies associated with dementia,
including lower folate, lower vitamin B12, elevated homocysteine, lower iron(42,
43), lower selenium (43,
44), lower Molybdenum (42),
and lower vitamin D.
Summary: Looking at the above solutions it
is apparent that if there single nutrient deficiency, specifically active
vitamin B2, the activity of the other nutrients, vitamin B12, iron, folate and
vitamin B6 will be compromised. This is very similar to the nutrient suggestions
suggested by the works of Douaud (9) and de Jager (10), who
have demonstrated the effectiveness of folate, vitamin B12 and vitamin B6, with
the addition of heme iron and vitamin B2. Curiously, lack of the single
nutrients selenium (55 ug/day) or molybdenum (100 ug/day) or iodine (150 ug/day),
could have similar effects due to their importance in the generation of active
B2 (FAD). Similarly, lack of vitamin B12 (6 ug/day), due to it's role in folate
processing, reducing homocysteine, stimulation of SAM, with resultant movement
of sulphur from methionine into the synthesis of iron-sulphur porteins, and the
resultant increase in energy production by the citric acid cycle through
aconitase activity. Apart from the nutrient suggestions,
it is generally accepted that obesity and lack of exercise both are associated
with a higher incidence of AD. Hence it would appear that a diet that is
nutrient rich and calorie sufficient, when combined with moderate amounts of
cardiovascular exercise, may be of considerable benefit to those wanting to
prevent, halt or even reverse the "dementia" process. The
probability that one can reverse the symptoms of dementia and thereby prevent
the onset of Alzheimer's Disease would depend upon finding a way to detect early
symptoms of the disease. Given that Alzheimer's Disease is regarded as a
classical mitochondrial disease, then assays that can determine the functional
activity of the mitochondria should be beneficial. Potential assays include
(i)
direct measurement of aconitase function
(ii) measurement of organic acids in
urine, or metabolic analysis. Currently Great Plains laboratory performs an
Organic Acids Test (http://www.greatplainslaboratory.com/organic-acids-test/ ),
whilst a similar metabolic test is also carried out by Genova (https://www.gdx.net/product/metabolic-analysis-test-organic-acids-urine
). Both of these tests are capable of identifying metabolic deficiencies that
could ultimately lead to dementia/AD.
(iii) measurement of iron status. Steady
decline in serum ferritin levels would be indicative of potential problems and
could be addressed relatively easily. Experience has show that once serum
ferritin levels drop below 70 ug/L, energy production from aconitase starts to
drop. This level of ferritin will not however be "flagged" by pathology
laboratories whose sole measurement relates to iron deficiency anaemia, rather
than to impending energy loss and functional loss of actonitase and
succinate dehydrogenase activity.
(iv) falling serum vitamin B12.
Falling functional vitamin B12 can be monitored by measuring an increase in the
metabolic products MMA and homocysteine. The so-called "active B12 assay" is a
complete misnomer, however falls in serum B12 and/or active B12 are
representative of loss of total vitamin B12 in serum. Loss of functional vitamin
B12 in the brain precedes loss in serum.
(v) reduced production of
Ubiquinone.
Falling functional vitamin B12 can be monitored by measuring reduced production
of Ubiquinone and hence reduced energy output in the electron transport chain.
Synthesis of Ubiquinone (CoQ10) requires 3 methylation steps during synthesis,
hence lack of methylation due to low methyl B12 levels reduces energy output due
to lack of production of CoQ10. A corresponding increase in the levels of
3-hydroxymethylglutarate is seen in the urine. Use of statins also reduces the
levels of CoQ10 is detrimental to energy production.
Lifestyle and Dementia and
Alzheimer's Disease It is known
that there are at least seven modifiable facts that increase the risk of
dementia.
These include, smoking, obesity, high blood pressure (hypertension), inactivity,
diabetes, depression and poor education. Of these, obesity, high blood pressure
(hypertension) and diabetes have all been shown to potentially be caused by low
vitamin B2 in the diet. Further, the level of obesity has been shown to be
inversely related to functional vitamin B12 levels and lower activity of
aconitase, resulting in lower energy output (34).
Regular exercise that raises the heart rate can increase the flow of blood to
the brain, and so reduce the risk of dementia. The exercise has to be intense
and increase cardiovascular fitness, as well as increasing the both the muscle
mass and muscle strength (35).
Additional benefit has been achieved with resistance training (36).
Furthermore, regular exercise can also help to reduce the risk of developing
dementia as it can help to reduce weight, decrease blood pressure and decrease
the risk of diabetes. Being
socially engaged, and participating in activities that stimulate the brain, such
as mental challenges and learning new skills, languages, or advanced learning
are all associated with a lowered incidence of dementia. Protect your
brain from damage. There are many instances where AD has arisen soon after a
mild or severe injury to the brain. Avoid
medications that can affect the uptake and processing of nutrients, including
antacids (Prilosec, Nexium, Zantac, Prevacid, Ranitidine, Famotidine, Nazitidine,
Cimetidine, etc), and MetforminTM. Avoid bariatric surgery, including bowel
resection or gastric by-pass surgery, as well as gastrectromy, particularly of
the cardiac or fundus. Avoid the
use of statins. Statins block the enzyme HMG-CoA-reductase, and in so doing
reduce the production of precursors involved in the production of ubiquinone,
and increase the potential energy output in the electron transport chain and
also increase the risk of cardiovascular disorder, depression and heart failure
(37) Further
information on preventing and early detection of diabetes can be found on many
sites, of which the following is but one
(PreventingType2diabetes).
Brain Training and Alzheimer's
Disease Prevention There are
several indications that exercising the brain can delay the onset of AD, and
George Mears from the Brain Wellness Institute (see
info@brainwellness.info) has kindly
submitted a summary of the latest suggestions for preventing dementia. These
suggestions can be found in the attached
document. The mechanism
whereby the "Brain Training" may have some effect may be as a result of the
dopamine reward from successful training experiences. It is known that there is
an age related loss of dopaminergic cell bodies in the brain (39),
and at least one study has shown that brain training is associated with changes
in the density of cortical dopamine D1 receptors (40).
Diet and Alzheimer's Disease
Prevention It is often
said that a diet that is good for the heart is good for the brain, and that the
best example of such a diet is the Mediterranean diet. More careful analysis
reveals that the diet is one of high nutrient density.
Whole
grains, brown rice and whole wheat pasta - providing vitamin B1, molybdenum and
iodine
Nuts, seeds
and beans - providing selenium, molybdenum, manganese and folate
Fresh fruit
and vegetables - providing folate and magnesium
Fish,
poultry, eggs, some red meat, clams, oysters, and mussels - providing zinc,
iodine, selenium, biotin, iron and vitamin B12
Milk,
cheese, and yoghurt - providing calcium, vitamin B2 and vitamin D.
Diets
containing sufficient amounts of vitamin B1 and vitamin B2 can also reduce the
risk of diabetes (a preventable risk factor for dementia), due to better blood
glucose control.
Diets high in
Iodine, Selenium and Molybdenum provide support for activation of vitamin B2 -
and essential co-factor for the activation of vitamin B12, vitamin D, iron and
metabolism of glucose and fats.
Studies on diets and healthy aging Further data
on diets and healthy aging can be found by looking at the following studies on
aging The Seven
Countries Study
http://www.sevencountriesstudy.com Lyon Diet
Heart Study
http://circ.ahajournals.org/content/circulationaha/99/6/779.full.pdf PREDIMED
Study
http://www.nejm.org/doi/full/10.1056/NEJMoa1200303 DASH Diet
http://dashdiet.org/ MIND Diet
https://www.ncbi.nlm.nih.gov/pubmed/16086182
https://www.ncbi.nlm.nih.gov/pubmed/25681666
Fang, M., Hu, J., Weiss, J. et
al. Lifetime
risk and projected burden of dementia. Nat
Med (2025).
https://doi.org/10.1038/s41591-024-03340-9
Clarke etal, 2014 Effects of homocysteine lowering
with B vitamins on cognitive ageing: meta-analysis of 11 trials with cognitive
data on 22,000 individuals.
PMID:
24965307
Habte etal,
2015 Iron, folate and vitamin B12 status of Ethiopian professional runners.
PMID: 26719754 Scheltens
etal, 1995 Histopathologic correlates of white matter changes on MRI in
Alzheimer's disease and normal aging.
PMID 7746401. Wynn and
Wynn, 1998 The danger of B12 deficiency in the elderly.
PMID
9836201 Bottiglieri
1996 Folate, vitamin B12, and neuropsychiatric disorders.PMID
9155210 Briani etal,
2013 Cobalamin deficiency: clinical picture and radiological findings.PDF Misra etal,
2003 Vitamin B12 deficiency neurological syndromes: a clinical, MRI and
electrodiagnostic study. PMID
12613142 De Jager,
2014 Critical levels of brain atrophy associated with homocysteine and cognitive
decline. PMID
24927906 Douaud etal
2013 Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin
treatment. PMID
23690582 Durga etal,
2007 Effect of 3-year folic acid supplementation on cognitive function in older
adults in the FACIT trial:... PMID
17240287 de Jager
etal, 2012 Cognitive and clinical outcomes of homocysteine-lowering B-vitamin
treatment in mild cognitive impairment: A randomized controlled trial.
PMID
21780182 Smith etal,
2010 Homocysteine-lowering by B vitamins slows the rate of accelerated brain
atrophy in mild cognitive impairment: A randomized controlled trial.
PMID
20838622
Harris etal, 2015 Improved
blood biomarkers but no cognitive effects from 16 weeks of multivitamin
supplementation in healthy older adults
PMID
25996285
Zhang etal, 2016 Decreased levels of vitamin B12 in aging,
autism and schizophrenia.
PMID
26799654
Garcua-Minguillan
etal, 2014 Riboflavin status modifies the effects of methylenetetrahydrofolate
reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms on
homocysteine
PMID 25322900
Shankle etal, 2016 CerefolinNAC therapy of hyperhomocysteinemia delays cortical
and white matter atrophy in Alzheimer's disease and cerebrovascular disease
PMID
27567825
Blundo etal, 2011. Vitamin B12 deficiency associated with symptoms of
frontotemporal dementia.
PMID
20927562
Katuoka etal, 1997 A case of vitamin B12 deficiency with broad neurological
disorders and canities.
PMID
9125735
Ikeda etal, 1992 Treatment of Alzheimer-type dementia with intravenous
mecobalamin.
PMID
1638504
Olivier
etal, 2009 Melatonin promotes oligodendroglial maturation of injured white
matter in neonatal rats.
PMID
1638504
Villapol
etal, 2011 Melatonin promotes myelination by decreasing white matter
inflammation after neonatal stroke
PMID
1638504
Turgut and Kaplan
2011 Effects of melatonin on peripheral nerve regeneration
PMID
17101822
Miller etal 2014 Antenatal antioxidant treatment with melatonin to decrease
newborn neurodevelopmental deficits and brain injury..
PMID
17101822
Onger etal
2017 Possible effects of some agents on the injured nerve in obese rats:.....
PMID
17101822 Higgins and
Flicker, 2003 Lecithin for dementia and cognitive impairment.
PMID
12917896
Cardoso etal, 2018 Supranutritional Sodium Selenate supplementation delivers
Selenium to the central nervous system:... PMID:
30215171 Moriyama
etal, 1996 Effects of dietary phosphatidylcholine on memory in memory deficient
mice with low brain acetylcholine. PMID:
8569416
Jiang etal, 2016 Partial BACE1 reduction in a Down syndrome mouse model blocks
Alzhemier-related endosomal anomalies and cholinergic neurodegeneration: role of
APP-CTF.
PMID: 26923405 Lombardo and
Maskos, 2015 Role of nicotinic acetylcholine receptor in Alzheimer's disease
pathology and treatment. PMID
25514383 Groth etal,
2014 Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and
Alzheimer's disease dementia. PMID
25059393
Lin etal, 2013 Chronic rapamycin restores brain vascular
integrity and function through NO synthase activation and improves memory in
symptomatic mice modeling Alzheimer's disease. PMID
23801246
de la Monte etal, 2000 Role of aberrant nitric oxide
synthase-3 expression in cerebrovascular degeneration and vascular-mediated
injury in Alzheimer's disease. PMID:
10818490
Austin etal, 2010 Endothelial nitric oxide modulates
expression and processing of amyloid precursor protein. PMID
21127294
Boyle etal, 2015 Physical activity, body mass index, and
brain atrophy in Alzheimer's Disease. PMID:
25248607
Ryuno etal, 2016 Differences in the association between high
blood pressure and cognitive functioning..... PMID:
27009579
Wlodek and Gonzales, 2003 Decreased energy levels can cause
and sustain obesity.. PMID:
14559057
Smith etal, 2010 Aerobic exercise and neurocognitive
performance: a meta-analytic review of randomized controlled trials .... PMID:
20223924
Bossers eatl, 2015 A 9-week aerobic and strength training
program improves cognitive and motor function in patients with dementia. PMID:
25648055
Maes etal, 2009 Lower plasma Coenzyme Q10 in depression: a
marker for treatment resistance and chronic fatigue in depression... PMID:
20010493
Palmer and DeKosky, 1993. Monoamine neurones in aging and
Alzheimer's disease. PMID:
19197069
McNab etal, 2009 Changes in cortical dopamine D1 receptor
binding associated with cognitive training.. PMID:
19197069
Annweiler 2016 Vitamin D in dementia prevention
PMID
27116242
Paglia etal 2016
Distinctive pattern of serum elements during the progression of Alzheimer's
disease
PMID
26957294
Smorgon etal 2004 Trace
elements and cognitive impairment: an elderly cohort studyMID
15207438
Van der Jeugd etal 2018
Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by
selenium ....
PMID
29691439
Taking Vitamin
D Could Help Prevent Dementia - Neuroscience News
Copyright © 2018 B12 Oils. All Rights Reserved.
The Potential Dietary Intervention
to Halt or Prevent Dementia or Reverse the
Development of Dementia and Alzheimer's Disease


Early Detection of Dementia and
Alzheimer's Disease
References
Reproduction in whole or in part in any form or medium without express written
permission is prohibited